



A SURESH G KARE Enterprise

## INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Santacruz (E), Mumbai 400 098

### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2010

(Rs. In Lacs)

Sr. No.	Particulars	Quarter ended 31.12.2010 (Unaudited)	Quarter ended 31.12.2009 (Unaudited)	Nine months ended 31.12.2010 (Unaudited)	Nine months ended 31.12.2009 (Unaudited)	Year ended 31.03.2010 (Audited)
1	<b>(a) Sales and Income from Operations</b>	<b>11,562</b>	9,678	<b>36,185</b>	29,233	<b>40,231</b>
	Less : Excise Duty	131	108	382	286	402
	<b>Net Sales and Income from Operations</b>	<b>11,431</b>	9,570	<b>35,803</b>	28,947	<b>39,829</b>
	<b>(b) Other Operating income</b>	<b>118</b>	26	<b>577</b>	319	<b>490</b>
	<b>Total</b>	<b>11,549</b>	9,596	<b>36,380</b>	29,266	<b>40,319</b>
2	<b>Expenditure :</b>					
	(a) (Increase)/Decrease in Finished Goods Stock in trade and work in progress	(693)	(186)	(1,636)	(260)	(593)
	(b) Consumption of raw materials	4,904	3,742	15,030	10,726	15,463
	(c) Purchase of traded goods	888	597	2,626	1,790	2,521
	(d) Employees cost	1,619	1,415	4,949	4,155	5,646
	(e) Depreciation	342	304	998	872	1,210
	(f) Research & Development Expenses	255	252	665	725	1,022
	(g) Other Expenditure	3,127	2,633	9,307	7,587	10,462
	(h) Total	10,442	8,757	31,939	25,595	35,731
3	<b>Profit from Operations before Other Income, Interest and Exceptional Items</b>	<b>1,107</b>	839	<b>4,441</b>	3,671	<b>4,588</b>
4	Other Income	2	1	3	15	16
5	<b>Profit before Interest and Exceptional Items</b>	<b>1,109</b>	840	<b>4,444</b>	3,686	<b>4,604</b>
6	Interest	59	60	177	219	291
7	<b>Profit after Interest but before Exceptional Items</b>	<b>1,050</b>	780	<b>4,267</b>	3,467	<b>4,313</b>
8	Exceptional Items	-	-	-	-	-
9	<b>Profit from Ordinary Activities before tax</b>	<b>1,050</b>	780	<b>4,267</b>	3,467	<b>4,313</b>
10	Tax Expenses - Current	210	133	851	587	731
	- Deferred	39	7	118	81	126
	- Prior Year	-	-	-	-	(22)
	- MAT Credit	(80)	(133)	(591)	(587)	(731)
11	<b>Net Profit from Ordinary Activities after tax</b>	<b>881</b>	773	<b>3,889</b>	3,386	<b>4,209</b>
12	Extraordinary Items	-	-	-	-	-
13	<b>Net Profit for the period</b>	<b>881</b>	773	<b>3,889</b>	3,386	<b>4,209</b>
14	Paid up Equity Share Capital (Face value Rs.10/- each)	1,228.67	1228.67	1,228.67	1228.67	1,228.67
15	Reserves excluding Revaluation Reserves	-	-	-	-	29,822
16	<b>Earning Per Share (EPS) - Not Annualised - Rs.</b>					
	(a) Basic and diluted EPS before Extraordinary Items	7.17	6.29	31.65	27.56	34.26
	(b) Basic and diluted EPS after Extraordinary Items	7.17	6.29	31.65	27.56	34.26
17	Public shareholding					
	- No of Shares	48,00,136	47,89,936	48,00,136	47,89,936	48,57,636
	- % of Shareholding	39.07	38.98	39.07	38.98	39.53
18	Promoters and promoters group shareholding					
	<b>a) Pledged/Encumbered</b>					
	- Number of shares	8,200	8,200	8,200	8,200	8,200
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.11	0.11	0.11	0.11	0.11
	- Percentage of shares (as a % of the total share capital of the company)	0.07	0.07	0.07	0.07	0.07
	<b>b) Non-encumbered</b>					
	- Number of shares	74,78,378	74,88,578	74,78,378	74,88,578	74,20,878
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	99.89	99.89	99.89	99.89	99.89
	- Percentage of shares (as a % of the total share capital of the company)	60.86	60.95	60.86	60.95	60.40

Notes :

- The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
- The figures for the previous periods have been regrouped and reclassified, wherever necessary.
- Summary of investor complaints : As on 01.10.2010 : Nil, Received during quarter: Nil, Resolved: Nil, Pending as on 31.12.2010 : Nil.
- The above results have been recommended by the Audit Committee and taken on record at the meeting of Board of Directors held on 20th January 2011 and have been subjected to a Limited Review by the Statutory Auditors of the Company.

By Order of the Board

Place : Mumbai  
Date : January 20, 2011

Suresh G. Kare  
Chairman & Managing Director